New Study Reveals Significant Challenges in Splitting Parkinson's Pills
In a recent research study published in Neurodegenerative Disease Management, Avion Pharmaceuticals, a subsidiary of Alora Pharmaceuticals, provided valuable insights into the real-world practices surrounding the treatment of Parkinson's disease, specifically focusing on the common practice of splitting carbidopa/levodopa tablets. The study, titled "Practices and Perceptions Around Splitting of Carbidopa/Levodopa Tablets: A Survey of Patients and Neurologists", was co-authored by a team of experts including Drs. Ramon L. Rodriguez, Stuart H. Isaacson, Yasar Torres-Yaghi, Rajesh Pahwa, and Ahmad Al-Sabbagh. It highlights significant challenges faced by patients, especially as the disease progresses.
Parkinson's disease is a progressive neurodegenerative disorder that primarily affects motor control. As the condition advances, patients often experience increased difficulties in self-managing their treatment, resulting in the need for adjustments in their medications. The findings from this survey underscore the frequent occurrence of splitting immediate-release carbidopa/levodopa tablets among these patients as a coping mechanism to manage their motor symptoms. However, the study reveals that this practice can become increasingly burdensome and imprecise, posing significant risks to effective treatment.
The research team gathered data from 101 patients living with Parkinson's disease and their caregivers, alongside input from 120 neurologists who specialize in movement disorder. The results show that a significant proportion of patients find that motor symptoms substantially affect their quality of life, particularly as they progress into the later stages of the disease. Notably, those with longer durations of the disease or greater difficulties in controlling their motor symptoms were more likely to report splitting their medication.
Among participants who split their pills, a mere 27% found the process easy. Additionally, only 18% of those who fragmented tablets into more than two pieces reported accuracy in achieving their desired doses.
Art Deas, CEO of Alora Pharmaceuticals, commented on the implications of these findings, stating, "The survey highlights a critical need for improved dosing flexibility and precision as Parkinson's disease evolves. Our product, DHIVY, aims to address these challenges by being the first functionally scored tablet of its kind. It allows for simple division into precise segments, enabling personalized dosing without the common inconveniences of traditional pill splitting."
Interestingly, the neurologists involved in the study also expressed growing dissatisfaction with current treatment options available for their patients as Parkinson's progresses. An estimated 45% of neurologists reported that they recommended their patients split carbidopa/levodopa tablets, while about 22% indicated that patients were doing so independently without physician guidance.
Overall, the survey results shed light on the critical need for collaboration among patients, caregivers, and healthcare providers, emphasizing the importance of addressing the complexities of treatment as Parkinson's disease progresses. By facilitating better communication and understanding between patients and medical professionals, it is possible to develop more effective strategies for managing the disease and improving the patients' quality of life.
About DHIVY
DHIVY® (carbidopa and levodopa) tablets are indicated for the treatment of Parkinson's disease. This innovative medication allows for the division of tablets into smaller dose segments, enhancing treatment customization. As with any medication, DHIVY should be taken as prescribed by healthcare providers.
About Alora Pharmaceuticals
Based in Alpharetta, GA, Alora Pharmaceuticals is committed to enhancing the quality of life for individuals with neurological disorders through innovative therapeutic aides and patient-focused support.
Conclusion
The findings from this recent study highlight the persistent challenges faced by those living with Parkinson's disease and urge for more comprehensive and user-friendly treatment options. Continued innovation and a focus on patient needs will be critical in the ongoing effort to improve standards of care in the field of neurodegenerative disorders.
Parkinson's disease is a progressive neurodegenerative disorder that primarily affects motor control. As the condition advances, patients often experience increased difficulties in self-managing their treatment, resulting in the need for adjustments in their medications. The findings from this survey underscore the frequent occurrence of splitting immediate-release carbidopa/levodopa tablets among these patients as a coping mechanism to manage their motor symptoms. However, the study reveals that this practice can become increasingly burdensome and imprecise, posing significant risks to effective treatment.
The research team gathered data from 101 patients living with Parkinson's disease and their caregivers, alongside input from 120 neurologists who specialize in movement disorder. The results show that a significant proportion of patients find that motor symptoms substantially affect their quality of life, particularly as they progress into the later stages of the disease. Notably, those with longer durations of the disease or greater difficulties in controlling their motor symptoms were more likely to report splitting their medication.
Among participants who split their pills, a mere 27% found the process easy. Additionally, only 18% of those who fragmented tablets into more than two pieces reported accuracy in achieving their desired doses.
Art Deas, CEO of Alora Pharmaceuticals, commented on the implications of these findings, stating, "The survey highlights a critical need for improved dosing flexibility and precision as Parkinson's disease evolves. Our product, DHIVY, aims to address these challenges by being the first functionally scored tablet of its kind. It allows for simple division into precise segments, enabling personalized dosing without the common inconveniences of traditional pill splitting."
Interestingly, the neurologists involved in the study also expressed growing dissatisfaction with current treatment options available for their patients as Parkinson's progresses. An estimated 45% of neurologists reported that they recommended their patients split carbidopa/levodopa tablets, while about 22% indicated that patients were doing so independently without physician guidance.
Overall, the survey results shed light on the critical need for collaboration among patients, caregivers, and healthcare providers, emphasizing the importance of addressing the complexities of treatment as Parkinson's disease progresses. By facilitating better communication and understanding between patients and medical professionals, it is possible to develop more effective strategies for managing the disease and improving the patients' quality of life.
About DHIVY
DHIVY® (carbidopa and levodopa) tablets are indicated for the treatment of Parkinson's disease. This innovative medication allows for the division of tablets into smaller dose segments, enhancing treatment customization. As with any medication, DHIVY should be taken as prescribed by healthcare providers.
About Alora Pharmaceuticals
Based in Alpharetta, GA, Alora Pharmaceuticals is committed to enhancing the quality of life for individuals with neurological disorders through innovative therapeutic aides and patient-focused support.
Conclusion
The findings from this recent study highlight the persistent challenges faced by those living with Parkinson's disease and urge for more comprehensive and user-friendly treatment options. Continued innovation and a focus on patient needs will be critical in the ongoing effort to improve standards of care in the field of neurodegenerative disorders.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.